Scheme meeting 2026
Logotype for Mayne Pharma Group Limited

Mayne Pharma Group (MYX) Scheme meeting 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Mayne Pharma Group Limited

Scheme meeting 2026 summary

17 Nov, 2026

Opening remarks and agenda

  • Gedeon Richter or its Australian subsidiary proposed acquiring all shares for A$6.40 cash per share, valuing equity at ~A$604m and representing a 99.4% premium to the 16 Nov 2026 closing price.

Financial performance review

  • Richter reported FY2025 sales of EUR 2.3bn and an EBIT margin of 31.5%; women’s healthcare sales were EUR 826m, with contraception and menopause contributing 68%.

  • Richter described itself as Europe’s second-largest women’s healthcare company.

Board and executive committee updates

  • Board unanimously recommends voting for the Scheme, absent a Superior Proposal and subject to the Independent Expert continuing to consider it in shareholders’ best interests.

  • Directors intend to vote shares they hold or control in favour, subject to the recommendation conditions; the CEO said business-as-usual operations and priorities continue until implementation.

  • The three largest shareholders, holding 22.14% of shares on issue together, intend to vote in favour, absent a Superior Proposal.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Mayne Pharma Group